Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates.

Snydman DR, McDermott LA, Jacobus NV, Kerstein K, Grossman TH, Sutcliffe JA.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02206-17. doi: 10.1128/AAC.02206-17. Print 2018 May.

2.

Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009.

Snydman DR, Jacobus NV, McDermott LA, Goldstein EJ, Harrell L, Jenkins SG, Newton D, Patel R, Hecht DW.

Anaerobe. 2017 Feb;43:21-26. doi: 10.1016/j.anaerobe.2016.11.003. Epub 2016 Nov 17.

PMID:
27867083
3.

Changes in the antibiotic susceptibility of anaerobic bacteria from 2007-2009 to 2010-2012 based on the CLSI methodology.

Hastey CJ, Boyd H, Schuetz AN, Anderson K, Citron DM, Dzink-Fox J, Hackel M, Hecht DW, Jacobus NV, Jenkins SG, Karlsson M, Knapp CC, Koeth LM, Wexler H, Roe-Carpenter DE; From the Ad Hoc Working Group on Antimicrobial Susceptibility Testing of Anaerobic Bacteria of CLSI.

Anaerobe. 2016 Dec;42:27-30. doi: 10.1016/j.anaerobe.2016.07.003. Epub 2016 Jul 15.

PMID:
27427465
4.

In Vitro Evaluation of the Activity of Imipenem-Relebactam against 451 Recent Clinical Isolates of Bacteroides Group and Related Species.

Snydman DR, Jacobus NV, McDermott LA.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6393-7. doi: 10.1128/AAC.01125-16. Print 2016 Oct.

5.

U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.

Snydman DR, McDermott LA, Jacobus NV, Thorpe C, Stone S, Jenkins SG, Goldstein EJ, Patel R, Forbes BA, Mirrett S, Johnson S, Gerding DN.

Antimicrob Agents Chemother. 2015 Oct;59(10):6437-43. doi: 10.1128/AAC.00845-15. Epub 2015 Aug 3.

6.

Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates.

Snydman DR, McDermott LA, Jacobus NV.

Antimicrob Agents Chemother. 2014;58(2):1218-23. doi: 10.1128/AAC.02253-13. Epub 2013 Nov 25.

7.

Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.

Snydman DR, Jacobus NV, McDermott LA.

Antimicrob Agents Chemother. 2012 Jun;56(6):3448-52. doi: 10.1128/AAC.06257-11. Epub 2012 Mar 5.

8.

Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009.

Snydman DR, Jacobus NV, McDermott LA, Golan Y, Goldstein EJ, Harrell L, Jenkins S, Newton D, Pierson C, Rosenblatt J, Venezia R, Gorbach SL, Queenan AM, Hecht DW.

Anaerobe. 2011 Aug;17(4):147-51. doi: 10.1016/j.anaerobe.2011.05.014. Epub 2011 Jun 2.

PMID:
21664469
9.

In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates.

Snydman DR, Jacobus NV, McDermott LA.

Antimicrob Agents Chemother. 2011 Jan;55(1):421-5. doi: 10.1128/AAC.00868-10. Epub 2010 Nov 1.

10.

Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).

Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJ, Harrell L, Jenkins S, Newton D, Pierson C, Rihs JD, Yu VL, Venezia R, Finegold SM, Rosenblatt JE, Gorbach SL.

Clin Infect Dis. 2010 Jan 1;50 Suppl 1:S26-33. doi: 10.1086/647940.

PMID:
20067390
11.

In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.

Snydman DR, Jacobus NV, McDermott LA.

Antimicrob Agents Chemother. 2008 Dec;52(12):4492-6. doi: 10.1128/AAC.00696-08. Epub 2008 Oct 6.

12.

National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.

Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, Finegold SM, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Yu V, Rihs J, Gorbach SL.

Antimicrob Agents Chemother. 2007 May;51(5):1649-55. Epub 2007 Feb 5.

14.

Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group.

Snydman DR, Jacobus NV, McDermott LA.

J Antimicrob Chemother. 2005 Jun;55(6):1024-8. Epub 2005 Apr 11.

PMID:
15824092
15.

In vitro activities of tigecycline against the Bacteroides fragilis group.

Jacobus NV, McDermott LA, Ruthazer R, Snydman DR.

Antimicrob Agents Chemother. 2004 Mar;48(3):1034-6.

16.

Emergence of fluoroquinolone resistance among Bacteroides species.

Golan Y, McDermott LA, Jacobus NV, Goldstein EJ, Finegold S, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Rihs J, Iannini P, Gorbach SL, Snydman DR.

J Antimicrob Chemother. 2003 Aug;52(2):208-13. Epub 2003 Jul 15.

PMID:
12865399
17.

In vitro activities of newer quinolones against bacteroides group organisms.

Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Goldstein E, Finegold S, Harrell L, Hecht DW, Jenkins S, Pierson C, Venezia R, Rihs J, Gorbach SL.

Antimicrob Agents Chemother. 2002 Oct;46(10):3276-9. Erratum in: Antimicrob Agents Chemother. 2003 Feb;47(2):831.

18.

National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000.

Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Goldstein EJ, Finegold SM, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Rihs J, Gorbach SL.

Clin Infect Dis. 2002 Sep 1;35(Suppl 1):S126-34.

PMID:
12173121
19.

Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.

Snydman DR, Jacobus NV, McDermott LA, Lonks JR, Boyce JM.

Antimicrob Agents Chemother. 2000 Dec;44(12):3447-50.

20.
21.

Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.

Snydman DR, Jacobus NV, McDermott LA, Supran S, Cuchural GJ Jr, Finegold S, Harrell L, Hecht DW, Iannini P, Jenkins S, Pierson C, Rihs J, Gorbach SL.

Antimicrob Agents Chemother. 1999 Oct;43(10):2417-22.

22.

In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT.

Antimicrob Agents Chemother. 1999 Apr;43(4):738-44.

23.

In vivo activities of peptidic prodrugs of novel aminomethyl tetrahydrofuranyl-1 beta-methylcarbapenems.

Weiss WJ, Mikels SM, Petersen PJ, Jacobus NV, Bitha P, Lin YI, Testa RT.

Antimicrob Agents Chemother. 1999 Mar;43(3):460-4.

24.

In vitro activities of aminomethyl-substituted analogs of novel tetrahydrofuranyl carbapenems.

Weiss WJ, Petersen PJ, Jacobus NV, Lin YI, Bitha P, Testa RT.

Antimicrob Agents Chemother. 1999 Mar;43(3):454-9.

25.

In vitro activity of piperacillin/tazobactam against isolates from patients enrolled in clinical trials.

Kuck NA, Jacobus NV, Spengler MD, Testa RT.

Int J Antimicrob Agents. 1996 May;7(1):15-21.

PMID:
18611730
26.

TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum beta-lactamases.

Bradford PA, Jacobus NV, Bhachech N, Bush K.

Antimicrob Agents Chemother. 1996 Jan;40(1):260-2.

27.

Susceptibility of enterococci, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae to the glycylcyclines.

Weiss WJ, Jacobus NV, Petersen PJ, Testa RT.

J Antimicrob Chemother. 1995 Jul;36(1):225-30.

PMID:
8537270
28.

Pyrroindomycins, novel antibiotics produced by Streptomyces rugosporus LL-42D005. II. Biological activities.

Singh MP, Petersen PJ, Jacobus NV, Mroczenski-Wildey MJ, Maiese WM, Greenstein M, Steinberg DA.

J Antibiot (Tokyo). 1994 Nov;47(11):1258-65.

29.

Glycothiohexides, novel antibiotics produced by "Sebekia" sp. LL-14E605. I. Taxonomy, fermentation and biological evaluation.

Steinberg DA, Bernan VS, Montenegro DA, Abbanat DR, Pearce CJ, Korshalla JD, Jacobus NV, Petersen PJ, Mroczenski-Wildey MJ, Maiese WM, et al.

J Antibiot (Tokyo). 1994 Aug;47(8):887-93.

30.

Mechanistic studies and biological activity of bioxalomycin alpha 2, a novel antibiotic produced by Streptomyces viridodiastaticus subsp. "litoralis" LL-31F508.

Singh MP, Petersen PJ, Jacobus NV, Maiese WM, Greenstein M, Steinberg DA.

Antimicrob Agents Chemother. 1994 Aug;38(8):1808-12.

31.

In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.

Testa RT, Petersen PJ, Jacobus NV, Sum PE, Lee VJ, Tally FP.

Antimicrob Agents Chemother. 1993 Nov;37(11):2270-7.

32.

Susceptibility of anaerobes in phase 3 clinical studies of piperacillin/tazobactam.

Jacobus NV, Immermann FW, Gupte JM, Testa RT.

Clin Infect Dis. 1993 Jun;16 Suppl 4:S344-8. No abstract available.

PMID:
8391862
33.

Microbiology and antibiotic resistance in odontogenic infections.

Gorbach SL, Gilmore WC, Jacobus NV, Doku HC, Tally FP.

Ann Otol Rhinol Laryngol Suppl. 1991 Sep;154:40-2. No abstract available.

PMID:
1952683
34.

In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I.

Petersen PJ, Jacobus NV, Weiss WJ, Testa RT.

Antimicrob Agents Chemother. 1991 Jan;35(1):203-7.

35.

The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.

Cornick NA, Cuchural GJ Jr, Snydman DR, Jacobus NV, Iannini P, Hill G, Cleary T, O'Keefe JP, Pierson C, Finegold SM.

J Antimicrob Chemother. 1990 Jun;25(6):1011-9.

PMID:
2370237
36.

Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group.

Cuchural GJ Jr, Tally FP, Jacobus NV, Cleary T, Finegold SM, Hill G, Iannini P, O'Keefe JP, Pierson C.

Antimicrob Agents Chemother. 1990 Mar;34(3):479-80.

37.
38.

Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.

Kuck NA, Jacobus NV, Petersen PJ, Weiss WJ, Testa RT.

Antimicrob Agents Chemother. 1989 Nov;33(11):1964-9.

39.

Synergistic activity of piperacillin: YTR-830H combinations in vitro and in vivo.

Kuck NA, Petersen PJ, Weiss WJ, Jacobus NV, Testa RT, Tally FP.

J Chemother. 1989 Jul;1(4 Suppl):105-6. No abstract available.

PMID:
16312325
40.

A prospective double-blind evaluation of penicillin versus clindamycin in the treatment of odontogenic infections.

Gilmore WC, Jacobus NV, Gorbach SL, Doku HC, Tally FP.

J Oral Maxillofac Surg. 1988 Dec;46(12):1065-70.

PMID:
3142979
41.

Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation.

Cuchural GJ Jr, Tally FP, Jacobus NV, Aldridge K, Cleary T, Finegold SM, Hill G, Iannini P, O'Keefe JP, Pierson C, et al.

Antimicrob Agents Chemother. 1988 May;32(5):717-22.

42.

Activity of trospectomycin against Bacteroides fragilis and other Bacteroides species.

Jacobus NV, Tally FP.

Antimicrob Agents Chemother. 1988 Apr;32(4):584-6.

43.

Colonization resistance of the human intestinal microflora: testing the hypothesis in normal volunteers.

Gorbach SL, Barza M, Giuliano M, Jacobus NV.

Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):98-102. Review.

PMID:
3132394
44.

In vitro activity of LY146032 against gram-positive bacteria.

Silva M, Jacobus NV, Gorbach SL.

Diagn Microbiol Infect Dis. 1988 Feb;9(2):79-85.

PMID:
2838217
45.

Antimicrobial resistance in oral and colonic bacteroides.

Crook DW, Cuchural GJ Jr, Jacobus NV, Tally FP.

Scand J Infect Dis Suppl. 1988;57:55-64. Review.

PMID:
3074473
46.

Activity of cefmetazole against anaerobic bacteria.

Cornick NA, Jacobus NV, Gorbach SL.

Antimicrob Agents Chemother. 1987 Dec;31(12):2010-2.

47.
48.

Antimicrobial substance from a human Lactobacillus strain.

Silva M, Jacobus NV, Deneke C, Gorbach SL.

Antimicrob Agents Chemother. 1987 Aug;31(8):1231-3.

49.

Effect of broad-spectrum parenteral antibiotics on "colonization resistance" of intestinal microflora of humans.

Barza M, Giuliano M, Jacobus NV, Gorbach SL.

Antimicrob Agents Chemother. 1987 May;31(5):723-7.

50.

Effect of broad-spectrum parenteral antibiotics on composition of intestinal microflora of humans.

Giuliano M, Barza M, Jacobus NV, Gorbach SL.

Antimicrob Agents Chemother. 1987 Feb;31(2):202-6.

Supplemental Content

Loading ...
Support Center